Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT05402384
PHASE2
AVTX-801 D-galactose Supplementation in SLC35A2-CDG
Sponsor: Eva Morava-Kozicz
View on ClinicalTrials.gov
Summary
This is a multicenter, randomized, double-blind, placebo-controlled, cross-over study to evaluate the efficacy and safety of AVTX-801 in subjects with SLC35A2-CDG
Official title: Evaluation of Efficacy and Safety of D-galactose Supplementation in SLC35A2-CDG, a Disorder of Hypogalactosylation
Key Details
Gender
All
Age Range
1 Month - Any
Study Type
INTERVENTIONAL
Enrollment
10
Start Date
2027-01
Completion Date
2028-03
Last Updated
2025-06-29
Healthy Volunteers
No
Interventions
DRUG
AVTX-801
Medical grade D-galactose dosage:2.0 g/kg/day
DRUG
Placebo
Matching placebo
Locations (1)
Mayo Clinic Minnesota
Rochester, Minnesota, United States